Bristol Myers Squibb announced the presentation of research across its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 30 – September 2, 2024, in London, England.

Data to be presented at the meeting includes long-term extension data evaluating the efficacy and safety profile of CAMZYOS (mavacamten) up to 180 weeks (3.5 years) for the treatment of New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM), as well as data on behalf of the BMS-Pfizer Alliance on ELIQUIS (apixaban) and the BMS-Johnson & Johnson Collaboration on milvexian.

"With the data to be presented from our cardiovascular franchise at this year’s ESC Congress, we continue to demonstrate our longstanding and unwavering commitment to improving the lives of patients impacted by cardiovascular diseases,” said Roland Chen, MD, senior vice president and head of Immunology, Cardiovascular & Neuroscience (ICN) Development at Bristol Myers Squibb. “We look forward to showcasing how we’re advancing development of our medicines for anticoagulation and thrombosis management as well as for the treatment of obstructive HCM for patients in need at the upcoming meeting.”